期刊
EXPERT OPINION ON EMERGING DRUGS
卷 16, 期 4, 页码 597-602出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728214.2011.644786
关键词
adenosine receptor; agonist; cancer; cardiac arrhythmia; cardiac perfusion imaging; G-protein-coupled receptor; inflammation; nucleoside; pain; rheumatoid arthritis
资金
- Intramural NIH HHS [ZIA DK031117-24] Funding Source: Medline
Adenosine receptors (ARs), the major targets of caffeine and theophylline, comprise four receptor subtypes designated as A(1), A(2A), A(2B) and A(3). Over a dozen AR agonists are currently in clinical trials for various conditions, including cardiac arrhythmias, neuropathic pain, myocardial perfusion imaging, cardiac ischemia, inflammatory diseases and cancer. Adenosine (nonselective), regadenoson (A(2A)) and dipyridamole (act indirectly via ARs) have received regulatory approval for clinical use. The present editorial will give a brief update on the current status of AR agonists in clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据